Physician profile
Erin B Amato
NPI 1447425178
$87,924.98
in general payments reported to CMS, 2019-2025
8 companies · $23K in 2025
The $23K reported for 2025 was more than what 97% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $22.90 · 2021: $191 · 2022: $32.46 · 2023: $25K · 2024: $39K · 2025: $23K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $77K · Travel and Lodging: $7,852 · Food and Beverage: $2,407.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $77,420.00 |
| Travel and Lodging | $7,852.00 |
| Food and Beverage | $2,406.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $87,723.32 | 2021-2025 | Spravato, Invega |
| Abbvie INC. | $58.71 | 2021-2023 | Vraylar |
| Novo Nordisk INC | $32.48 | 2023 | Wegovy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $32.18 | 2021-2023 | |
| Alkermes, INC. | $22.90 | 2020 | |
| Supernus Pharmaceuticals, INC. | $21.08 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $18.49 | 2022 | |
| Neurocrine Biosciences, INC. | $15.82 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erin Amato listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.